leadf
logo-loader
viewAshmore Group

Ashmore Group the top mid cap faller as Barclays slashes fund manager's target price to 270p

The bank’s analysts noted that despite a 19% drop by the stock in the final quarter of last 2016, it still remains the most expensive in the sector.

Fund manager
Ashmore shares were still up 11% over the year and outperformed their asset manager peers in 2016

Emerging markets-focused fund manager Ashmore group PLC (LON:ASHM) was the top mid cap faller this morning after Barclays slashed its target and reiterated an ‘underweight’ stance on the stock.

In a note to clients, the bank’s analysts cut their price target for Ashmore to 270p from 325p, noting that despite a 19% drop by the stock in the final quarter of 2016, it still remains the most expensive in the sector.

They pointed out that Ashmore shares were still up 11% over the year and outperformed their asset manager peers in 2016.

The analysts said: "We remain cautious on emerging markets-exposed names, given rising US yields and deteriorating EM sentiment after the US elections.”

They added that a continued decline in volatility in US interest rates appears a necessary condition for emerging markets flows to stabilise further, which seems unlikely in the near term given economic policy uncertainty.

The analysts also cut their assets under management estimates for Ashmore for both full-year June 2017 and June 2018 to indicate declines of 8-9%.

In mid morning trading, Ashmore shares on the FTSE 250 index were down over 6%, or 18.7p to 280.6p.

Quick facts: Ashmore Group

Price: 454.2961 GBX

LSE:ASHM
Market: LSE
Market Cap: £32.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Mountain Valley MD gets approval for COVID-19 clearance trial in Level 4 Bio...

Mountain Valley MD (CSE: MVMD) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling with news the company will be conducting a Bio-Safety Level 4 lab study of COVID-19 viral clearance to prove out the Company’s solubilized Ivermectin technology versus commercially...

3 hours, 38 minutes ago

2 min read